ZLK

zafirlukast


Toggle HydrogenToggle Labels

Chemical Component Summary

Namezafirlukast
Identifierscyclopentyl ~{N}-[3-[[2-methoxy-4-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-methyl-indol-5-yl]carbamate
FormulaC31 H33 N3 O6 S
Molecular Weight575.675
TypeNON-POLYMER
Isomeric SMILESCc1ccccc1S(=O)(=O)NC(=O)c2ccc(c(c2)OC)Cc3cn(c4c3cc(cc4)NC(=O)OC5CCCC5)C
InChIInChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
InChIKeyYEEZWCHGZNKEEK-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count74
Chiral Atom Count0
Bond Count78
Aromatic Bond Count22

Drug Info: DrugBank

DrugBank IDDB00549 
NameZafirlukast
Groups
  • approved
  • investigational
DescriptionZafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Synonyms
  • cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate
  • Zafirlukast
  • 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
Brand Names
  • Accolate Tab 20 mg
  • Accolate
  • Zafirlukast
IndicationFor the prophylaxis and chronic treatment of asthma.
Categories
  • Acids, Acyclic
  • Agents to Treat Airway Disease
  • Amides
  • Anti-Asthmatic Agents
  • Carbamates
ATC-CodeR03DC01
CAS number107753-78-6

Drug Targets

NameTarget SequencePharmacological ActionActions
Cysteinyl leukotriene receptor 1MDETGNLTVSSATCHDTIDDFRNQVYSTLYSMISVVGFFGNGFVLYVLIK...unknownantagonist
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknownsubstrate,inhibitor
Cytochrome P450 2C8MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...unknowninhibitor
Prostaglandin G/H synthase 1MSRSLLLWFLLFLLLLPPLPVLLADPGAPTPVNPCCYYPCQHQGICVRFG...unknownsubstrate
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL603
PubChem 5717
ChEMBL CHEMBL603
ChEBI CHEBI:10100
CCDC/CSD AHILOU, MAJQOE, MAJQUK, AHIHEG, AHIHAC, MAJQIY
COD 4513448, 2014421, 2014422, 4513446, 2014420